This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07010432 |
|---|---|
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Novo Nordisk A/S |
| Enrollment | 144 participants |
| Design | Interventional, Randomized, Parallel, Masking: Quadruple |
| Conditions | Obesity |
| Interventions | Cagrilintide; Semaglutide; Placebo cagrilintide; Placebo semaglutide |
| Start | Jun 12, 2025 |
| Primary completion | May 3, 2028 |
| Study completion | May 3, 2028 |
| Results posted | Not yet |
| Registry last updated | Sep 10, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
In this study we will investigate how the medicine cagrilintide affects bone health in women after menopause with obesity during weight loss, compared to treatment with placebo (the dummy medicine with no active substances) and semaglutide. The purpose is to examine whether cagrilintide can reduce the decline in bone mass associated to weight loss. Participants will either get cagrilintide, semaglutide, CagriSema (cagrilintide combined with semaglutide) or placebo. Which treatment participants get is decided by chance. Semaglutide is already approved for the treatment of overweight and obesity and can be prescribed by doctors. Cagrilintide and CagriSema are new medications currently under development for weight management. The study will last for about 79 weeks.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Relative change in volumetric bone mineral density (vBMD) of the total hip assessed by quantitative computed tomography (QCT) | From baseline to end of treatment (week 68) |
13 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
